Bedwetting (enuresis) in children: causes, alarm therapy, and desmopressin

Understanding bedwetting — the basics

Bedwetting — medically called nocturnal enuresis — means regularly wetting the bed during sleep in a child aged 5 or over. It is extremely common, normal, and almost always involuntary. The Royal Children’s Hospital Melbourne estimates that about 15–20% of 5-year-olds, 10% of 7-year-olds, and 5% of 10-year-olds wet the bed regularly. Without treatment, spontaneous resolution occurs at a rate of approximately 15% per year — meaning most children are dry well before adolescence. About 1–2% of 15-year-olds and 0.5–1% of adults have ongoing enuresis.

The International Children’s Continence Society (ICCS) distinguishes between:

• Primary nocturnal enuresis (PNE) — the child has never achieved a sustained dry period of 6 months
• Secondary enuresis — bedwetting returns after at least 6 months of being reliably dry
• Monosymptomatic — bedwetting only, with no daytime urinary symptoms
• Non-monosymptomatic — bedwetting plus daytime urgency, frequency, or incontinence

Secondary and non-monosymptomatic enuresis require broader investigation. Monosymptomatic primary nocturnal enuresis — the most common form — has a well-established management ladder.

A. Core clinical — the AU general practice framework

The three-system model

eTG and RACGP both explain primary nocturnal enuresis as arising from a combination of three factors:

1. Nocturnal polyuria — some children have a relatively blunted overnight rise in antidiuretic hormone (ADH), producing a larger volume of urine overnight than the bladder can comfortably hold
2. Reduced functional bladder capacity or detrusor overactivity — the bladder is smaller or more reactive than average, filling to triggering point before morning
3. Failure of arousal — the child does not wake in response to bladder fullness signals that reach the brain during sleep

Genetic factors are strong: there is approximately 75% concordance in children when both parents were bedwetters as children, and several chromosomal loci have been identified.

Constipation — the most overlooked driver

Before any specific enuresis treatment is started, constipation must be identified and treated. A full rectum physically compresses the bladder through the pelvic floor, reduces its functional capacity, and interferes with the neurological signals that would normally arouse a child from sleep. Treating constipation alone resolves or substantially improves bedwetting in a significant proportion of children. Ask specifically about stool frequency and consistency, soiling, and abdominal discomfort. Palpate the abdomen for a faecal mass.

Red flags and secondary causes

Always perform a urine dipstick at the first assessment — glycosuria indicates possible diabetes; leucocytes and nitrites indicate UTI.

Red flags requiring further investigation:

• Daytime symptoms (urgency, frequency, incontinence) — warrant renal tract ultrasound and broader workup
• Constant dribble in a girl — possible ectopic ureter until excluded
• Weak or strained stream in a boy — possible posterior urethral valves
• Polyuria and polydipsia with weight loss — diabetes mellitus
• Sacral dimple, hair tuft, lower-limb weakness, or gait change — possible spinal cord tethering (MRI indicated)
• Snoring and witnessed breathing pauses — obstructive sleep apnoea; adenotonsillar hypertrophy is a common and treatable cause
• Secondary enuresis with sudden onset — UTI, diabetes, psychosocial stress, or abuse
• Significant developmental regression or behavioural change

History and examination

A good history includes:

• Pattern — primary vs secondary; nightly vs occasional; number of wets per night
• Daytime voiding — urgency, frequency, dribble, holding postures (crossing legs, squatting)
• Bowel habit — stool frequency, consistency, soiling or faecal incontinence
• Fluid intake — total volume, timing, caffeine or fizzy drinks in the afternoon or evening
• Sleep — depth, snoring, witnessed apnoeas, restless sleep
• Family history — parents’ enuresis history
• Psychosocial — recent stressors, school function, friendships
• Impact — child’s distress, sleepovers refused, parental sleep disruption

Examination: growth chart and blood pressure; abdominal palpation; inspection of the lower back for sacral dimples or hair tufts; lower limb neurological assessment; genital examination if symptoms suggest structural causes; oropharynx if obstructive sleep apnoea is suspected.

B. The management ladder

Step 0 — treat co-morbidities first

Treat constipation, UTI, or obstructive sleep apnoea before starting enuresis-specific treatment. These commonly resolve bedwetting on their own and, if untreated, substantially reduce treatment success.

Step 1 — education, reassurance, and lifestyle adjustments

RCH Melbourne guidelines and RACGP both emphasise that the foundation of every management plan is:

Reassurance and de-stigmatisation. Bedwetting is not laziness, bad behaviour, or a sign of emotional disturbance. The child is not choosing to wet the bed. Never punish a child for bedwetting — this does not improve and often worsens the situation by adding anxiety and shame. Involve the child in management decisions in an age-appropriate way.

Fluid distribution:

• Ensure adequate daytime fluid intake — spreading 60% before midday, 30% in the afternoon, and limiting drinks in the 1–2 hours before bed
• Avoid caffeine and carbonated drinks, particularly in the afternoon and evening

Bladder habits:

• Regular daytime voiding every 2–3 hours; empty the bladder before bed
• A “double void” (void, wait a few minutes, then void again before bed) can help

Reward systems: Use reward charts only for behaviours the child can control — drinking pattern, voiding before bed. Do not use rewards for dry nights — the child has no direct control over this and rewarding it reinforces inappropriate guilt for wet nights.

Practical measures: waterproof mattress covers; a change of pyjamas and sheets made easy. Pull-ups can be used for practical reasons but should be removed during alarm therapy trials.

The Continence Foundation Australia national helpline (1800 33 00 66) provides family support, resources, and information on alarm hire programmes.

Step 2 — bedwetting alarm therapy (first-line for school-aged children)

Bedwetting alarm therapy is the gold standard treatment. The Cochrane systematic review demonstrates cure rates of 60–80% at 6 months — the most durable of any available treatment. When the alarm stops, most children stay dry; in contrast, relapse rates after stopping desmopressin are very high.

How alarms work: a moisture-sensitive probe — either a mat under the sheet or a small sensor clipped to the child’s underwear — triggers an audible or vibrating alarm when wetting begins. With repetition over weeks to months, the brain learns to either wake before wetting starts or to contract the urethral sphincter during sleep. This is a conditioned learning process.

Practical requirements:

• Commit for 8–16 weeks upfront — families who stop early do not achieve results
• Parents need to wake with the child initially, especially in deep sleepers
• Stop criterion: 14 consecutive dry nights constitutes success
• Relapse occurs in about 30% — a second alarm trial is usually effective

Alarm types available in Australia include bell-and-pad mat systems and wireless body-worn devices (clip to underwear). Wireless/vibrating alarms suit shared bedrooms or hearing-impaired children. Purchase costs are $100–250; the Continence Foundation Australia and some hospital services offer hire schemes. NDIS may fund alarms for children with disabilities.

Step 3 — desmopressin (PBS Authority Required)

Desmopressin (brand names Minirin Melt, Minirin) is a synthetic analogue of ADH that concentrates overnight urine, reducing the volume produced during sleep. It is effective in approximately 60% of children during treatment. It is PBS Authority Required (Streamlined) for primary nocturnal enuresis in children aged 6 years and over.

Dosing per eTG:

• Minirin Melt sublingual 120 mcg taken at bedtime; increase to 240 mcg if response is inadequate
• Minirin tablet 200 mcg taken at bedtime; increase to 400 mcg if response is inadequate
• The intranasal spray formulation is not used for enuresis (regulatory restriction due to higher hyponatraemia risk)

Critical safety rule — fluid restriction: restrict fluid from 1 hour before the dose until 8 hours after taking it. Giving desmopressin without reducing fluid intake can cause water intoxication with severe hyponatraemia, which may cause seizures. Withhold the dose during any illness involving vomiting, diarrhoea, or high fluid intake.

When to use desmopressin:

• Short-term situations where a dry night is important — school camps, sleepovers, sporting events
• As an adjunct to alarm therapy in children who are alarm-resistant
• When families are unable or unwilling to use alarm therapy

Relapse on stopping desmopressin occurs in about 70% of cases. Gradual dose reduction rather than abrupt stopping may reduce relapse. A 4–6 week initial course with reassessment is standard.

Step 4 — combined alarm and desmopressin

For children who are refractory to either alarm or desmopressin alone, combining both treatments improves outcomes in some studies. This is typically managed in a specialist continence clinic.

Step 5 — specialist referral

Refer to a paediatric continence clinic or paediatric urology for:

• Daytime incontinence or suspected voiding dysfunction
• Structural concerns — continuous dribble, weak stream, recurrent UTI
• Red-flag neurological signs
• Failed combination therapy
• Significant psychological sequelae — school refusal, social isolation, depression

Anticholinergics (oxybutynin, tolterodine) are used for overactive bladder contributing to non-monosymptomatic enuresis — generally under specialist guidance. Tricyclic antidepressants (imipramine) are a historical last-resort option, rarely used today due to cardiotoxicity and overdose risk.

C. Daytime incontinence — different problem, broader workup

Daytime wetting (diurnal incontinence) always warrants investigation beyond what is needed for monosymptomatic nocturnal enuresis. Common causes include:

• Overactive bladder — sudden urgency with leak; treat with bladder retraining (timed voiding every 2 hours, double voiding) plus anticholinergics if needed after excluding structural causes
• Dysfunctional voiding — uncoordinated bladder–sphincter contraction leading to incomplete emptying and recurrent UTI
• Vaginal voiding in girls — urine pools in the vagina and leaks post-void; simple posture correction (voiding with knees apart) resolves it
• Continuous dribble — possible ectopic ureter in girls; posterior urethral valves in boys; needs renal tract ultrasound and specialist assessment

A renal tract ultrasound is standard for daytime incontinence or when structural causes are possible. Routine renal tract ultrasound for straightforward monosymptomatic primary nocturnal enuresis without daytime symptoms is low yield and not recommended by NICE CG111 or RCH Melbourne.

D. Australian operations — MBS, PBS, and resources

Standard GP consultation items (23, 36, 44) apply. A longer Level D consultation (item 44) at first presentation allows time for comprehensive history, examination, education, and management planning. Telehealth equivalents are appropriate for follow-up, dose titration, and alarm progress review.

PBS prescribing: desmopressin (Minirin Melt, Minirin) requires Streamlined Authority for primary nocturnal enuresis in patients aged 6 and over — confirm the current streamlined authority code from the PBS schedule. Oxybutynin and tolterodine are PBS-listed for overactive bladder.

NDIS funding is available for children with disability and persistent incontinence — covering continence products, physiotherapy, and behavioural support. The Continence Aids Payment Scheme (CAPS) provides approximately $700 per year toward continence products for children aged 5 and over with a permanent or chronic condition causing significant incontinence.

The Continence Foundation Australia helpline (1800 33 00 66) provides free family support, resources in multiple languages, and information on alarm hire.

E. Special populations

Adolescents: bedwetting in adolescence carries significant psychosocial impact — social isolation, refusal of camps and sleepovers, reduced self-esteem. Address sensitively with privacy and autonomy. Combined alarm and desmopressin is often needed. Screen opportunistically for diabetes, OSA, alcohol use, and mental health.

Aboriginal and Torres Strait Islander families: engage culturally safe pathways through Aboriginal and Torres Strait Islander health services. Cultural beliefs about night-time practices and family expectations vary; kinship engagement supports adherence. 13YARN (13 92 76) provides culturally safe crisis support for Aboriginal and Torres Strait Islander families.

Refugee and CALD families: interpreter services support assessment; explore beliefs about bedwetting and treatment. Refugee health may include psychological trauma as a contributing factor.

Children with disability: alarm therapy may not be suitable for children with significant cognitive impairment. Product-based management and NDIS-funded supports are central. Discuss with the child’s paediatrician.

Twins and siblings sharing a bedroom: wireless or vibrating alarms avoid disturbing others.

When to escalate

Seek medical review:

• Bedwetting that returned after 6 months of being dry (secondary enuresis) — needs investigation
• Daytime wetting of any kind — fuller workup
• Constant dribble (not intermittent wetting) — structural cause
• Bedwetting with polydipsia, polyuria, or weight loss — diabetes
• Snoring, choking during sleep, daytime sleepiness — obstructive sleep apnoea
• Sacral dimple, hair tuft, lower limb weakness, or gait abnormality — possible tethered spinal cord
• Significant distress, school refusal, or behavioural change — psychological support and specialist input

What this article is and is not

This is general health information drawn from RCH Melbourne, eTG, RACGP, Continence Foundation Australia, Cochrane, and NICE CG111. It does not constitute personal medical advice. Always discuss your child’s specific situation with your own GP or paediatrician.

Australian consumer resources: HealthDirect — Bedwetting, Continence Foundation Australia, Sydney Children’s Hospital Network.

For crisis support: Lifeline 13 11 14, Beyond Blue 1300 22 4636, 13YARN 13 92 76 (Aboriginal and Torres Strait Islander peoples).

---

Sources cited

1. Royal Children’s Hospital Melbourne — Nocturnal enuresis CPG
2. Continence Foundation Australia
3. International Children’s Continence Society
4. eTG complete — paediatric enuresis
5. RACGP — Bedwetting
6. Cochrane Reviews — Alarm therapy for enuresis
7. NICE CG111 — Nocturnal enuresis
8. Australian Medicines Handbook
9. PBS — Desmopressin Authority Required
10. HealthDirect — Bedwetting
11. Sydney Children’s Hospital Network — Enuresis